Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 25, 2026, 2:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 12,899 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adult Disease Clear all
Completed Phase 3 Interventional Results available

A Study in Adults With Type 1 Diabetes

NCT01421147
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
LY2963016, Lantus, Insulin Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
21
States / cities
Birmingham, Alabama • Hollywood, Florida • New Port Richey, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Jul 25, 2026, 2:40 PM EDT
Active, not recruiting Phase 3 Interventional

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

NCT00978458
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neurotoxicity
Interventions
temozolomide, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
168
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 117 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Jul 25, 2026, 2:40 PM EDT
Terminated Phase 1 Interventional

Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma

NCT02258555
View directory record Official record
Conditions
Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
Interventions
GS-9901
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
6
States / cities
Duarte, California • Fresno, California • Whittier, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Jul 25, 2026, 2:40 PM EDT
Not listed Not applicable Interventional

Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain

NCT00087815
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Radiation Toxicity
Interventions
dexamethasone, hyperbaric oxygen, cognitive assessment, magnetic resonance imaging, positron emission tomography, quality-of-life assessment
Drug · Procedure
Lead sponsor
Barrett Cancer Center
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Jul 25, 2026, 2:40 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study to Evaluate the Hypoglossal Nerve Stimulator in Adolescents With Down Syndrome and Obstructive Sleep Apnea

NCT02344108
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Down Syndrome
Interventions
Inspire® Upper Airway Simulation System (Model 3028 IPG )
Device
Lead sponsor
Christopher Hartnick, M.D.
Other
Eligibility
10 Years to 21 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Jul 25, 2026, 2:40 PM EDT
Recruiting Not applicable Interventional

GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes

NCT07228117
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MiniMed™ NMX8-AID System with DS5™/Simplera Sync™
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
7 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
33
States / cities
Little Rock, Arkansas • Escondido, California • Goleta, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 25, 2026, 2:40 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older

NCT06695117
View directory record Official record
Conditions
COVID-19 Immunization, Influenza Immunization
Interventions
IIV-HD, rC19 (dose 1), IIV-HD + rC19 (dose 1), IIV-HD + rC19 (dose 2), IIV-HD + rC19 (dose 3), IIV-HD + rC19 (dose 4), Placebo (0.9% NaCl)
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
980 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
12
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 25, 2026, 2:40 PM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

NCT05117489
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Miricorilant 150 mg, Miricorilant 100 mg, Miricorilant 50 mg, Miricorilant 10 mg
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Chandler, Arizona • Tucson, Arizona • Panorama City, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Jul 25, 2026, 2:40 PM EDT
Recruiting Phase 2 Interventional

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT00801489
View directory record Official record
Conditions
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, de Novo Myelodysplastic Syndrome, High Risk Myelodysplastic Syndrome, Inv(16), Myelodysplastic Syndrome With Excess Blasts, t(16;16), t(8;21), Untreated Adult Acute Myeloid Leukemia
Interventions
Cytarabine, Decitabine, Filgrastim-sndz, Fludarabine Phosphate, Gemtuzumab Ozogamicin, Idarubicin, Laboratory Biomarker Analysis
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 25, 2026, 2:40 PM EDT
Completed Phase 3 Interventional Results available

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

NCT03881696
View directory record Official record
Conditions
Peanut Allergy, Multi-food Allergy
Interventions
Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 55 Years
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Jul 25, 2026, 2:40 PM EDT
Completed Not applicable Interventional

Clinical Performance of Posterior Composite Tooth Fillings in Adults

NCT03175627
View directory record Official record
Conditions
Dental Caries, Dental Restoration Failure
Interventions
Filtek One, Filtek Z250
Device
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Jul 25, 2026, 2:40 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

NCT06431373
View directory record Official record
Conditions
Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Interventions
Brepocitinib PO QD, Placebo PO QD
Drug
Lead sponsor
Priovant Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
53
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 25, 2026, 2:40 PM EDT
Not yet recruiting Phase 3 Interventional

52-week Open Label Safety-Tolerability Study

NCT07369154
View directory record Official record
Conditions
Schizophrenia
Interventions
LB-102
Drug
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
23
States / cities
Chandler, Arizona • Bentonville, Arkansas • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 25, 2026, 2:40 PM EDT
Completed Phase 3 Interventional

Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

NCT00259922
View directory record Official record
Conditions
Bowel Dysfunction, Constipation
Interventions
Placebo, Alvimopan, Alviompan
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
119
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 104 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Jul 25, 2026, 2:40 PM EDT
Recruiting Not applicable Interventional

Mobile CBT for Middle Aged and Older Adults

NCT05754151
View directory record Official record
Conditions
Anxiety Disorders and Symptoms, Depressive Symptoms, Depression
Interventions
MAYA Mobile Application
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 25, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

NCT00274924
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
104
States / cities
Palo Alto, California • Fort Collins, Colorado • Jacksonville, Florida + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Jul 25, 2026, 2:40 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine in Healthy Adults

NCT03051386
View directory record Official record
Conditions
Venezuelan Equine Encephalomyelitis Virus Disease
Interventions
VEE Vaccine
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Jul 25, 2026, 2:40 PM EDT
Completed Phase 3 Interventional

Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma

NCT02565173
View directory record Official record
Conditions
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD, timolol 0.5% BID, placebo BID
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Jul 25, 2026, 2:40 PM EDT
Recruiting No phase listed Observational

Tissue Collection for Studies of Lymph Cancer

NCT01676805
View directory record Official record
Conditions
Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Lymphomatoid Granulomatosis, Leukemia-Lymphoma, Adult T-Cell
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 25, 2026, 2:40 PM EDT
Completed Phase 2 Interventional Results available

To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD

NCT00612456
View directory record Official record
Conditions
Macular Degeneration
Interventions
Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
Tucson, Arizona • Beverly Hills, California • Pasadena, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Jul 25, 2026, 2:40 PM EDT
Completed Phase 4 Interventional Results available

CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib

NCT01227577
View directory record Official record
Conditions
Chronic Myelogenous Leukemia in Chronic Phase
Interventions
Nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
32
States / cities
Anaheim, California • Burbank, California • Concord, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Jul 25, 2026, 2:40 PM EDT
Active, not recruiting Not applicable Interventional

FAMS-T1D Self-Regulation and Social Support for T1D

NCT05820477
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
FAMS-T1D, Digital resources for diabetes
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 24 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Jul 25, 2026, 2:40 PM EDT
Completed Not applicable Interventional

Using Immersive Virtual Reality to Treat Complex Regional Pain Syndrome in Adults

NCT05888142
View directory record Official record
Conditions
Pain, Chronic
Interventions
in clinic pain VR reduction exercises, In clinic VRpain reduction exercises + VR homeworks
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Jul 25, 2026, 2:40 PM EDT
Not listed Phase 1 Interventional

IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma

NCT00003842
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
interleukin-4 PE38KDEL cytotoxin, isolated perfusion, surgical procedure
Biological · Drug · Procedure
Lead sponsor
Barrett Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Jul 25, 2026, 2:40 PM EDT